Merus falls as FDA extends review of cancer therapy

Merus NV

05/11/2024 14:56

** U.S.-listed shares of therapy developer Merus N.V.
 2GH.F   MRUS.O  fall 4.4% to $49
    ** Co says the U.S. FDA extended the review of Merus'
gene-targeting cancer therapy to allow sufficient time to assess
some recent information submitted by the company
    ** Co says it had submitted additional data about the
therapy's manufacturing process and quality control, in response
to a request from the FDA
    ** The health agency will now decide on the treatment
zenocutuzumab by Feb. 4, 2025, compared with a previous action
date of Nov. 6 this year
    ** Stock up 78% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))